Potential value of bacteriocins in the etiological treatment of infectious diseases of the respiratory tract

А.Е. Abaturov, Т.А. Kryuchko

Abstract


Bacteriocins are ribosomal-synthesized hydrophobic antimicrobial peptides with a broad antimicrobial spectrum of action. Gram-positive bacteria are the main source of bacteriocins. Bacteriocins of different classes acting on Gram-positive and Gram-negative bacteria use different molecular mechanisms, the functioning of which leads to disruption of the integrity of the cell wall or inhibition of the synthesis of nucleic acids and proteins of targeted bacteria. Currently, more than 100 lantibiotic peptides are described in the literature. Many of them are used to develop future medicines. Several lantibiotics are currently undergoing clinical and preclinical trials, including bioengineering lantibiotics, which can play a key role in overcoming the antibiotic resistance of bacterial pathogens.

Keywords


infectious diseases of the respiratory tract; children; bacteriocins

References


Abriouel H, Franz CM, Ben Omar N, Gálvez A. Diversity and applications of Bacillus bacteriocins. FEMS Microbiol Rev. 2011 Jan;35(1):201-32. doi: 10.1111/j.1574-6976.2010.00244.x.

Ahmad V, Khan MS, Jamal QM, Alzohairy MA, Al Karaawi MA, Siddiqui MU. Antimicrobial potential of bacteriocins: in therapy, agriculture and food preservation. Int J Antimicrob Agents. 2017 Jan;49(1):1-11. doi: 10.1016/j.ijantimicag.2016.08.016.

Castiglione F, Cavaletti L, Losi D, et al. A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp. Biochemistry. 2007 May 22;46(20):5884-95. doi: 10.1021/bi700131x.

Chatterjee C, Paul M, Xie L, van der Donk WA. Biosynthesis and mode of action of lantibiotics. Chem Rev. 2005 Feb;105(2):633-84. doi: 10.1021/cr030105v.

Cotter PD, Ross RP, Hill C. Bacteriocins - a viable alternative to antibiotics? Nat Rev Microbiol. 2013 Feb;11(2):95-105. doi: 10.1038/nrmicro2937.

De Kwaadsteniet M, Doeschate KT, Dicks LM. Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett Appl Microbiol. 2009 Jan;48(1):65-70. doi: 10.1111/j.1472-765X.2008.02488.x.

Donaldson SH, Galietta L. New pulmonary therapies directed at targets other than CFTR. Cold Spring Harb Perspect Med. 2013 Jun; 3(6): a009787. doi: 10.1101/cshperspect.a009787.

Field D, Cotter PD, Hill C, Ross RP. Bioengineering Lantibiotics for Therapeutic Success. Front Microbiol. 2015; 6: 1363. doi: 10.3389/fmicb.2015.01363.

Khosa S, Lagedroste M, Smits SH. Protein Defense Systems against the Lantibiotic Nisin: Function of the Immunity Protein NisI and the Resistance Protein NSR. Front Microbiol. 2016 Apr 12;7:504. doi: 10.3389/fmicb.2016.00504.

Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother. 2004 Sep;54(3):648-53. doi: 10.1093/jac/dkh387.

Lohans CT, Vederas JC. Development of Class IIa Bacteriocins as Therapeutic Agents. Int J Microbiol. 2012;2012:386410. doi: 10.1155/2012/386410.

Ongey EL, Yassi H, Pflugmacher S, Neubauer P. Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies. Biotechnol Lett. 2017 Apr;39(4):473-482. doi: 10.1007/s10529-016-2279-9.

Ongey EL, Neubauer P. Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical production. Microb Cell Fact. 2016 Jun 7;15:97. doi: 10.1186/s12934-016-0502-y.

Piper C, Draper LA, Cotter PD, Ross RP, Hill C. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother. 2009 Sep;64(3):546-51. doi: 10.1093/jac/dkp221.

Rios AC, Moutinho CG, Pinto FC, et al. Alternatives to overcoming bacterial resistances: State-of-the-art. Microbiol Res. 2016 Oct;191:51-80. doi: 10.1016/j.micres.2016.04.008.

Shin JM, Gwak JW, Kamarajan P, Fenno JC, Rickard AH, Kapila YL. Biomedical applications of nisin. J Appl Microbiol. 2016 Jun;120(6):1449-65. doi: 10.1111/jam.13033.

Singh S, ho Lee M, Park I, Shin Y, Lee YS. Antimicrobial seafood packaging: a review. J Food Sci Technol. 2016 Jun; 53(6): 2505–2518. doi: 10.1007/s13197-016-2216-x.

Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004 May;119 Suppl:13-6. PMID: 15232154.




DOI: https://doi.org/10.22141/2224-0551.12.7.2017.116187

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Zdorov'ye Rebenka - Child`s Health

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru